Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Elos Medtech

BATS-CHIXE:ELOSBS
Snowflake Description

Undervalued with proven track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ELOSBS
BATS-CHIXE
SEK592M
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

Elos Medtech AB (publ) develops and manufactures medical devices and components for the medtech industry. The last earnings update was 49 days ago. More info.


Add to Portfolio Compare Print
  • Elos Medtech has significant price volatility in the past 3 months.
ELOSBS Share Price and Events
7 Day Returns
12.5%
BATS-CHIXE:ELOSBS
-1.2%
GB Medical Equipment
0.1%
GB Market
1 Year Returns
-9.5%
BATS-CHIXE:ELOSBS
-0.3%
GB Medical Equipment
-23.6%
GB Market
ELOSBS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Elos Medtech (ELOSBS) 12.5% -24.3% -35.2% -9.5% -21.7% -
GB Medical Equipment -1.2% -12% -19.1% -0.3% -2.3% 20.9%
GB Market 0.1% -15.5% -27% -23.6% -24.3% -23.5%
1 Year Return vs Industry and Market
  • ELOSBS underperformed the Medical Equipment industry which returned -0.3% over the past year.
  • ELOSBS outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -23.6% over the past year.
Price Volatility
ELOSBS
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Elos Medtech undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Elos Medtech to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Elos Medtech.

BATS-CHIXE:ELOSBS Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.5%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BATS-CHIXE:ELOSBS
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 5.4%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.81
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.808 (1 + (1- 22%) (55.34%))
1.105
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.1
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (1.105 * 5.44%)
6.54%

Discounted Cash Flow Calculation for BATS-CHIXE:ELOSBS using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Elos Medtech is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BATS-CHIXE:ELOSBS DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 6.54%)
2020 23.00 Analyst x1 21.59
2021 48.00 Analyst x1 42.29
2022 69.00 Analyst x1 57.06
2023 85.07 Est @ 23.29% 66.03
2024 99.08 Est @ 16.46% 72.18
2025 110.65 Est @ 11.68% 75.66
2026 119.87 Est @ 8.34% 76.94
2027 127.06 Est @ 5.99% 76.55
2028 132.60 Est @ 4.36% 74.98
2029 136.85 Est @ 3.21% 72.63
Present value of next 10 years cash flows SEK635.00
BATS-CHIXE:ELOSBS DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= SEK136.85 × (1 + 0.53%) ÷ (6.54% – 0.53%)
SEK2,289.22
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK2,289.22 ÷ (1 + 6.54%)10
SEK1,215.00
BATS-CHIXE:ELOSBS Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK635.00 + SEK1,215.00
SEK1,850.00
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK1,850.00 / 8.07
SEK229.3
BATS-CHIXE:ELOSBS Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BATS-CHIXE:ELOSBS represents 1.0112x of OM:ELOS B
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
1.0112x
Value per Share
(Listing Adjusted, SEK)
= Value per Share (SEK) x Listing Adjustment Factor
= SEK 229.30 x 1.0112
SEK231.87
Value per share (SEK) From above. SEK231.87
Current discount Discount to share price of SEK72.20
= -1 x (SEK72.20 - SEK231.87) / SEK231.87
68.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Elos Medtech is available for.
Intrinsic value
>50%
Share price is SEK72.2 vs Future cash flow value of SEK231.87
Current Discount Checks
For Elos Medtech to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Elos Medtech's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Elos Medtech's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Elos Medtech's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Elos Medtech's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BATS-CHIXE:ELOSBS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in SEK SEK4.77
OM:ELOS B Share Price ** OM (2020-04-07) in SEK SEK71.4
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PE Ratio Median Figure of 11 Publicly-Listed Medical Equipment Companies 25.55x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 748 Publicly-Listed Companies 12.61x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Elos Medtech.

BATS-CHIXE:ELOSBS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:ELOS B Share Price ÷ EPS (both in SEK)

= 71.4 ÷ 4.77

14.96x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Elos Medtech is good value based on earnings compared to the GB Medical Equipment industry average.
  • Elos Medtech is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Elos Medtech's expected growth come at a high price?
Raw Data
BATS-CHIXE:ELOSBS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 14.96x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
16.5%per year
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PEG Ratio Median Figure of 8 Publicly-Listed Medical Equipment Companies 2x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 517 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

BATS-CHIXE:ELOSBS PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 14.96x ÷ 16.5%

0.91x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Elos Medtech is good value based on expected growth next year.
Price based on value of assets
What value do investors place on Elos Medtech's assets?
Raw Data
BATS-CHIXE:ELOSBS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in SEK SEK66.92
OM:ELOS B Share Price * OM (2020-04-07) in SEK SEK71.4
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry PB Ratio Median Figure of 20 Publicly-Listed Medical Equipment Companies 2.83x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,323 Publicly-Listed Companies 1.11x
BATS-CHIXE:ELOSBS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:ELOS B Share Price ÷ Book Value per Share (both in SEK)

= 71.4 ÷ 66.92

1.07x

* Primary Listing of Elos Medtech.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Elos Medtech is good value based on assets compared to the GB Medical Equipment industry average.
X
Value checks
We assess Elos Medtech's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Elos Medtech has a total score of 5/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Elos Medtech expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Elos Medtech expected to grow at an attractive rate?
  • Elos Medtech's earnings growth is expected to exceed the low risk savings rate of 0.5%.
Growth vs Market Checks
  • Elos Medtech's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
  • Elos Medtech's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
BATS-CHIXE:ELOSBS Future Growth Rates Data Sources
Data Point Source Value (per year)
BATS-CHIXE:ELOSBS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 16.5%
BATS-CHIXE:ELOSBS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 2.6%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.1%
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BATS-CHIXE:ELOSBS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BATS-CHIXE:ELOSBS Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 730 106 55 1
2021-12-31 664 82 37 1
2020-12-31 613 91 23 1
BATS-CHIXE:ELOSBS Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2019-12-31 689 103 39
2019-09-30 700 107 35
2019-06-30 697 95 32
2019-03-31 679 67 29
2018-12-31 645 66 21
2018-09-30 625 66 24
2018-06-30 603 58 21
2018-03-31 593 59 23
2017-12-31 578 62 23
2017-09-30 562 68 18
2017-06-30 556 86 23
2017-03-31 552 90 29

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Elos Medtech's earnings are expected to grow by 16.5% yearly, however this is not considered high growth (20% yearly).
  • Elos Medtech's revenue is expected to grow by 2.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BATS-CHIXE:ELOSBS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Elos Medtech Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:ELOSBS Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 6.81 6.81 6.81 1.00
2021-12-31 4.55 4.55 4.55 1.00
2020-12-31 2.88 2.88 2.88 1.00
BATS-CHIXE:ELOSBS Past Financials Data
Date (Data in SEK Millions) EPS *
2019-12-31 4.77
2019-09-30 4.33
2019-06-30 4.01
2019-03-31 3.61
2018-12-31 2.76
2018-09-30 3.44
2018-06-30 3.19
2018-03-31 3.70
2017-12-31 3.74
2017-09-30 2.98
2017-06-30 3.87
2017-03-31 4.75

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Elos Medtech is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Elos Medtech's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Elos Medtech has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Elos Medtech performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Elos Medtech's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Elos Medtech's year on year earnings growth rate has been positive over the past 5 years.
  • Elos Medtech's 1-year earnings growth exceeds its 5-year average (83.9% vs 9.3%)
  • Elos Medtech's earnings growth has exceeded the GB Medical Equipment industry average in the past year (83.9% vs -9.5%).
Earnings and Revenue History
Elos Medtech's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Elos Medtech Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BATS-CHIXE:ELOSBS Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 689.40 38.50 133.30 17.20
2019-09-30 700.01 34.94 131.44 20.96
2019-06-30 697.01 32.34 129.24 21.56
2019-03-31 678.91 29.14 125.64 20.86
2018-12-31 644.71 20.94 120.84 19.26
2018-09-30 624.72 24.41 117.62 14.10
2018-06-30 603.12 21.01 112.72 13.20
2018-03-31 592.72 22.51 108.92 13.80
2017-12-31 577.92 22.61 105.92 13.80
2017-09-30 562.29 18.03 107.82 15.33
2017-06-30 556.49 23.43 107.32 15.93
2017-03-31 552.49 28.73 103.92 15.43
2016-12-31 551.99 26.43 101.22 15.33
2016-09-30 554.66 26.69 96.47 15.20
2016-06-30 551.06 19.89 94.67 15.00
2016-03-31 538.56 15.39 93.87 14.70
2015-12-31 503.66 16.09 93.27 13.90
2015-09-30 473.86 17.48 86.62 12.67
2015-06-30 435.66 23.48 80.42 11.27
2015-03-31 397.86 25.78 71.72 10.47
2014-12-31 380.86 23.38 63.22 9.87
2014-09-30 371.26 25.15 61.80 9.74
2014-06-30 369.06 18.15 60.00 9.54
2014-03-31 365.96 16.65 59.40 9.34
2013-12-31 368.16 16.95 59.20 9.14
2013-09-30 395.85 19.55 66.02 9.73
2013-06-30 412.85 18.45 72.32 10.73

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Elos Medtech has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Elos Medtech used its assets less efficiently than the GB Medical Equipment industry average last year based on Return on Assets.
  • Elos Medtech has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Elos Medtech's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Elos Medtech has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Elos Medtech's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Elos Medtech's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Elos Medtech is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Elos Medtech's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Elos Medtech's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Elos Medtech Company Filings, last reported 3 months ago.

BATS-CHIXE:ELOSBS Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 539.90 327.70 55.20
2019-09-30 551.60 346.00 57.70
2019-06-30 534.60 327.30 51.80
2019-03-31 534.40 308.00 26.00
2018-12-31 508.48 260.92 48.96
2018-09-30 503.80 287.80 41.90
2018-06-30 507.20 280.10 47.00
2018-03-31 489.60 299.10 76.10
2017-12-31 368.99 302.48 9.62
2017-09-30 356.70 322.30 21.70
2017-06-30 364.60 329.80 16.40
2017-03-31 371.90 351.30 35.90
2016-12-31 366.84 315.86 38.50
2016-09-30 355.10 353.30 32.10
2016-06-30 343.40 366.60 18.00
2016-03-31 333.80 0.00 51.40
2015-12-31 330.60 287.23 40.50
2015-09-30 333.70 0.00 24.50
2015-06-30 326.80 0.00 35.20
2015-03-31 344.20 0.00 130.80
2014-12-31 338.62 129.87 125.53
2014-09-30 334.30 0.00 136.60
2014-06-30 328.10 0.00 77.80
2014-03-31 237.60 0.00 28.20
2013-12-31 232.85 143.92 31.19
2013-09-30 222.00 183.20 25.90
2013-06-30 213.90 193.40 29.90
  • Elos Medtech's level of debt (55%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (38% vs 55% today).
  • Debt is well covered by operating cash flow (34.6%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 4.2x coverage).
X
Financial health checks
We assess Elos Medtech's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Elos Medtech has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Elos Medtech's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
2.1%
Current annual income from Elos Medtech dividends. Estimated to be 1.77% next year.
If you bought SEK2,000 of Elos Medtech shares you are expected to receive SEK42 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Elos Medtech's pays a lower dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (2.59%).
  • Elos Medtech's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (7.08%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BATS-CHIXE:ELOSBS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.2%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 588 Stocks 5.6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.3%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.6%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BATS-CHIXE:ELOSBS Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2022-12-31 1.30 1.00
2021-12-31 1.30 1.00
2020-12-31 1.20 1.00
BATS-CHIXE:ELOSBS Past Annualized Dividends Data
Date (Data in SEK) Dividend per share (annual) Avg. Yield (%)
2020-02-18 1.500 1.840
2019-03-29 1.000 1.025
2019-02-18 1.000 1.423
2018-10-25 0.000 0.000
2018-07-19 0.000 0.000
2018-04-24 0.000 0.000
2018-04-03 0.000 0.000
2018-02-27 0.000 0.000
2018-02-19 0.000 0.000
2017-04-27 1.300 1.599
2016-04-27 1.000 1.011
2015-04-02 2.000 1.818
2015-01-15 2.000 2.358
2014-04-02 2.000 2.801
2014-02-21 2.000 2.798
2013-03-27 1.000 1.859
2013-02-22 1.000 2.339
2012-03-28 1.500 4.323
2012-02-24 1.500 3.218
2011-03-30 1.500 2.852
2011-02-25 1.500 2.724
2010-10-27 0.000 0.000
2010-08-19 0.000 0.000
2010-04-30 0.000 0.000
2010-01-15 0.000 0.000
2010-01-04 0.000 0.000

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Elos Medtech has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
  • Elos Medtech has only been paying a dividend for 9 years, and since then there has been no growth.
Current Payout to shareholders
What portion of Elos Medtech's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (3.2x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (5.2x coverage).
X
Income/ dividend checks
We assess Elos Medtech's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Elos Medtech afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Elos Medtech has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Elos Medtech's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jan Wahlström
AGE 52
TENURE AS CEO 3.8 years
CEO Bio

Mr. Jan Wahlström has been the Chief Executive Officer and President of Elos Medtech AB since July 1, 2016. Mr. Wahlström joined Elos Medtech from his role as President of Larodan AB. Mr. Wahlström served as the Chief Executive Officer of Biolin Scientific AB (publ) from April 26, 2010 to February 1, 2013 and served as its Chief Operating Officer. Mr. Wahlström served as the Chief Executive Officer and Sales Manager of Europe at MKS Data Analytics Solutions since May 2005. Mr. Wahlström has been with the Biolin Scientific since 2007 as Managing Director for the subsidiary Q-Sense and Sales Director for the group. He served as Chief Executive Officer of Q-Sense from 2007 to 2010. He served as Nordic Sales Manager for Waters. He has several years experience from the scientific instrument field from companies like Waters Corp. and Skandinaviska Genetech. He serves as the Chairman of the Board at Insplorion AB. He has a background from AstraZeneca process R&D and Pharmacia R&D in analytical chemistry. Mr. Wahlström studied chemistry in Uppsala and has a marketing degree from IHM.

CEO Compensation
  • Insufficient data for Jan to compare compensation growth.
  • Insufficient data for Jan to establish whether their remuneration is reasonable compared to companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Elos Medtech management team in years:

3.8
Average Tenure
49.5
Average Age
  • The tenure for the Elos Medtech management team is about average.
Management Team

Jan Wahlström

TITLE
President & CEO
AGE
52
TENURE
3.8 yrs

Ewa Linsäter

TITLE
Chief Financial Officer
AGE
49
TENURE
0.8 yrs

Malin Gustavsson

TITLE
Marketing Director
AGE
47

Anders Björklund

TITLE
QA/RA Quality Director
AGE
44

Sören Larsson

TITLE
President of Forshemgruppen AB
AGE
54
TENURE
17.3 yrs

Søren Olesen

TITLE
CEO of Elos Medtech Pinol A/S & Business Unit Director of Dental
AGE
58

Mathias Andersson

TITLE
Chief Executive Officer of Elos Medtech Microplast AB
AGE
48

Jodie Gilmore

TITLE
CEO of Elos Medtech Onyx & Business Unit Director of Orthopedics
AGE
48

Conny Jakobsson

TITLE
Chief Executive Officer of Elos Medtech Tianjin Co. Ltd
AGE
50

Sam Svännel

TITLE
Chief Executive Officer of Elos Medtech Timmersdala AB
AGE
58
Board of Directors Tenure

Average tenure and age of the Elos Medtech board of directors in years:

3.1
Average Tenure
61.5
Average Age
  • The tenure for the Elos Medtech board of directors is about average.
Board of Directors

Yvonne Mårtensson

TITLE
Chairman
COMPENSATION
SEK400K
AGE
66
TENURE
3.3 yrs

Claes Hansson

TITLE
Director
AGE
62
TENURE
1.3 yrs

Jeppe Magnusson

TITLE
Director
COMPENSATION
SEK175K
AGE
67
TENURE
8.3 yrs

Anders Birgersson

TITLE
Director
COMPENSATION
SEK175K
AGE
61
TENURE
4 yrs

Jon Risfelt

TITLE
Director
COMPENSATION
SEK225K
AGE
58
TENURE
3 yrs

Hanna Wilkman

TITLE
Director
AGE
52
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • Elos Medtech individual insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (SEK) Value (SEK)
24. Mar 20 Sell Mathias Andersson Individual 24. Mar 20 24. Mar 20 -19,000 SEK66.76 SEK-1,268,440
14. Mar 20 Buy Mathias Andersson Individual 13. Mar 20 13. Mar 20 500 SEK74.00 SEK37,000
19. Jul 19 Buy Mathias Andersson Individual 18. Jul 19 19. Jul 19 1,000 SEK101.50 SEK96,767
06. May 19 Buy Jan Wahlström Individual 06. May 19 06. May 19 1,000 SEK87.00 SEK87,000
X
Management checks
We assess Elos Medtech's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Elos Medtech has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Elos Medtech AB (publ) develops and manufactures medical devices and components for the medtech industry. The company operates in three segments: Orthopedics, Dental, and Life Science. Its products include implants, screws, plates, instruments, drills, pins and wires, prosthetics, digital dentistry workflow products, disposable plastics, HPLC fittings, and other medical plastic parts, as well as original equipment manufacturing products. The company also provides design and development, regulatory, prototyping, testing, process validation, and supply and inventory management, as well as design for manufacturing and engineering services. It has operations in Sweden, Denmark, China, and the United States. The company was formerly known as Elos AB (publ) and changed its name to Elos Medtech AB (publ) in April 2015. Elos Medtech AB (publ) was founded in 1923 and is based in Gothenburg, Sweden.

Details
Name: Elos Medtech AB (publ)
ELOSBS
Exchange: BATS-CHIXE
Founded: 1923
SEK592,191,200
8,068,000
Website: http://www.elosmedtech.com
Address: Elos Medtech AB (publ)
Torsgatan 5B,
Gothenburg,
Västra Götaland County, 411 04,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM ELOS B Series B Shares OMX Nordic Exchange Stockholm SE SEK 07. May 1993
LSE 0IZX Series B Shares London Stock Exchange GB SEK 07. May 1993
BATS-CHIXE ELOSBS Series B Shares BATS 'Chi-X Europe' GB SEK 07. May 1993
Number of employees
Current staff
Staff numbers
566
Elos Medtech employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 21:28
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/04/03
Last earnings filing: 2020/02/18
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.